Please enable JavaScript.
Coggle requires JavaScript to display documents.
Rwanda’s Rapid Marburg Outbreak Response under 100-Day Mission - Coggle…
Rwanda’s Rapid Marburg Outbreak Response under 100-Day Mission
I. Pre-Outbreak Preparedness
Government Commitment
Rwanda MoH adopts CEPI’s 100DM
Establishes 100DM Office within MoH
Partnerships Established
Public-private partnerships: MoH, CEPI, Sabin, IQVIA, BioNTech
National Ethics Committee and Rwanda FDA onboarded
Capacity Building
Table-top exercises simulating hypothetical outbreak (e.g., Rift Valley Fever)
Training for rapid trial design, site prep, and community engagement
II. Outbreak Detection & Early Response (Day 0–3)
Case Detected (e.g., index case – miner in Kigali)
Outbreak Declared (e.g., Sept 27, 2024)
Immediate Notification
Rwanda contacts CEPI & Sabin
Vaccine supply and trial team alerted
III. Rapid Research Mobilization (Day 4–9)
Protocol Adaptation
WHO CORE protocol adapted for local context
Decision made for open-label Phase 2 trial over ring trial
Regulatory Approvals
Rwanda FDA & National Ethics Committee fast-track review
Parallel Activities
Vaccine import clearance, cold chain logistics
Trial site readiness ensured by IQVIA and RBC
IV. Clinical Trial Launch (Day 10)
Trial Start
Vaccination begins for frontline workers & high-risk contacts
Trial formally initiated with GCP compliance
Vaccine Delivery
Shipment from Sabin's partner (ReiThera, Italy) received
Communication
Daily coordination among partners
Clear public messaging to maintain trust
V. Outcomes
Vaccination Completed: >1,700 people vaccinated by end of October
Outbreak Controlled: Only 17 new cases after trial launch
Trial Continues: Safety and immunogenicity being monitored
Preparedness Validated: Rwanda becomes global model
🛠️ Key Enablers
Pre-existing investigational vaccine with Phase 1 data
Strong coordination & trust between partners
Trained local research staff and infrastructure
Community trust and communication strategies
Regulatory agility and ethics readiness